Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine

AbbottAbbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine's "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.

"As an innovation-driven company, Abbott relies on the diversity of our people to provide different ideas, perspectives and experience that enable us to translate science into new solutions for patients," said Stephen Fussell, senior vice president, Human Resources, Abbott.

Diversity a Long-Standing Priority for Abbott
Abbott's commitment to diversity starts at the top with the company's Chairman and Chief Executive Officer Miles D. White, who chairs the company's Executive Inclusion Council. The Council oversees the company's diversity and inclusion efforts, monitors the hiring and advancement of women and minorities in management, and supports programs that promote an inclusive work environment for all employees.

Abbott maintains aggressive goals for the recruitment, hiring and retention of women and minorities. Minorities at Abbott make up more than one-quarter (26 percent), and women nearly one-half (47 percent), of Abbott's total U.S. workforce. Abbott has increased the number of minorities in management by 68 percent and the number of women in management by 64 percent over the past five years.

More than 7,700 employees participate in Abbott's employee networks, which play a vital role in building more diverse leadership within Abbott. These include: LA VOICE Network (Hispanic/Latino), Women Leaders in Action, Black Business Network, Asian Cultural Leadership Network, PRIDE Network gay/lesbian) and the Part-Time Network. By focusing on career development, mentoring, informal networking and work-life integration, Abbott's active networks offer leadership and expanded advancement opportunities for women and minorities. Each network is sponsored by a member of senior management who helps align the group's objectives with Abbott's business strategy.

Abbott Widely Recognized as a Premier Employer
In addition to being included in Hispanic Business magazine's "Diversity Elite 60," Abbott has been included on DiversityInc magazine's list of the "Top 50 Companies for Diversity" for four years. The company was named one of the "Top 50 Companies for Black MBAs to Work" by Black MBA magazine, and has been recognized for many years by FORTUNE magazine as one of the "Best Companies for Minorities."

Abbott also has been included in Working Mother magazine's "100 Best Companies for Working Mothers" for the past seven years, has been named one of the "50 Best Places to Launch a Career" by BusinessWeek and was included in the 2008 edition of the Princeton Review's Best Entry-Level Jobs. In addition, Abbott has been recognized by Science and The Scientist magazines as a top employer for scientists, and FORTUNE has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...